Pruritus - Pipeline Insight, 2021
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “Pruritus - Pipeline Insight, 2021,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Pruritus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Pruritus: Overview
Pruritus, also known as itching is defined as an unpleasant sensation that provokes the desire to scratch. Beyond an itching sensation, symptoms of pruritus can include redness, blisters, dry, cracked and scaly skin. Itch has been categorized into the following four classifications: cutaneous, neuropathic, neurogenic, and psychogenic. Pruritus, or itch, is most commonly associated with a primary skin disorder such as xerosis, atopic dermatitis, drug eruption, urticaria, psoriasis, arthropod assault, mastocytosis, dermatitis herpetiformis, or pemphigoid. Diagnostic testing is directed by the clinical evaluation and may include a complete blood count and measurement of thyroid-stimulating hormone, serum bilirubin, alkaline phosphatase, serum creatinine, and blood urea nitrogen levels. The treatment of pruritus includes topical agents, systemic agents, physical modalities, and non-pharmacological treatments.
'Pruritus - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pruritus pipeline landscape is provided which includes the disease overview and Pruritus treatment guidelines. The assessment part of the report embraces, in depth Pruritus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pruritus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Pruritus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Pruritus Emerging Drugs
Further product details are provided in the report..
Pruritus: Therapeutic Assessment
This segment of the report provides insights about the different Pruritus drugs segregated based on following parameters that define the scope of the report, such as:
Pruritus: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Pruritus therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pruritus drugs.
Pruritus Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Pruritus - Pipeline Insight, 2021,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Pruritus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Pruritus: Overview
Pruritus, also known as itching is defined as an unpleasant sensation that provokes the desire to scratch. Beyond an itching sensation, symptoms of pruritus can include redness, blisters, dry, cracked and scaly skin. Itch has been categorized into the following four classifications: cutaneous, neuropathic, neurogenic, and psychogenic. Pruritus, or itch, is most commonly associated with a primary skin disorder such as xerosis, atopic dermatitis, drug eruption, urticaria, psoriasis, arthropod assault, mastocytosis, dermatitis herpetiformis, or pemphigoid. Diagnostic testing is directed by the clinical evaluation and may include a complete blood count and measurement of thyroid-stimulating hormone, serum bilirubin, alkaline phosphatase, serum creatinine, and blood urea nitrogen levels. The treatment of pruritus includes topical agents, systemic agents, physical modalities, and non-pharmacological treatments.
'Pruritus - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pruritus pipeline landscape is provided which includes the disease overview and Pruritus treatment guidelines. The assessment part of the report embraces, in depth Pruritus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pruritus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Pruritus R&D. The therapies under development are focused on novel approaches to treat/improve Pruritus.
This segment of the Pruritus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Pruritus Emerging Drugs
- Difelikefalin: Cara Therapeutics
- BLU-5937: BELLUS Health
Further product details are provided in the report..
Pruritus: Therapeutic Assessment
This segment of the report provides insights about the different Pruritus drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Pruritus
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Pruritus: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Pruritus therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pruritus drugs.
Pruritus Report Insights
- Pruritus Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Pruritus drugs?
- How many Pruritus drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pruritus?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pruritus therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Pruritus and their status?
- What are the key designations that have been granted to the emerging drugs?
- Cara Therapeutics
- BELLUS Health
- Regeneron
- Maruho
- Trevi Therapeutics
- AbbVie
- Lumosa Therapeutics
- 9 Meters Biopharma
- Atridia
- Suzhou Connect Biopharmaceuticals
- Avior Bio
- Saniona
- DermaXon
- Akari Therapeutics
- Difelikefalin
- BLU-5937
- Dupilumab
- M-5250
- T 111
- Onabotulinum toxin A
- LT-5001
- RDD1609
- SHR-0410
- CBP-174
- AV-104
- SAN-711
- DX-412
- Votucalis
Introduction
Executive Summary
Pruritus: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Pruritus – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Pruritus companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Pruritus Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Preregistration)
Comparative Analysis
Difelikefalin: Cara Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
BLU-5937: BELLUS Health
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I/II)
Comparative Analysis
LT-5001: Lumosa Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical/Discovery Stage Products
Comparative Analysis
SAN-711: Saniona
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Pruritus Key Companies
Pruritus Key Products
Pruritus- Unmet Needs
Pruritus- Market Drivers and Barriers
Pruritus- Future Perspectives and Conclusion
Pruritus Analyst Views
Pruritus Key Companies
Appendix
Executive Summary
Pruritus: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Pruritus – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Pruritus companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Pruritus Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Preregistration)
Comparative Analysis
Difelikefalin: Cara Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
BLU-5937: BELLUS Health
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I/II)
Comparative Analysis
LT-5001: Lumosa Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical/Discovery Stage Products
Comparative Analysis
SAN-711: Saniona
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Pruritus Key Companies
Pruritus Key Products
Pruritus- Unmet Needs
Pruritus- Market Drivers and Barriers
Pruritus- Future Perspectives and Conclusion
Pruritus Analyst Views
Pruritus Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Pruritus
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Pruritus
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Pruritus
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Pruritus
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
